 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 GLOBE NEWSWIRE -- Akero Therapeutics, Inc. Nasdaq: AKRO, a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis NASH, today reported second quarter financial results for the period ending June 30, 2021. 